Completion of the assessment of orlistat containing medicinal products
19.03.2012
European Medicines Agency has completed the assessment of anti-obesity medicines containing orlistat by which it considered that very rare cases of severe liver injury that have been reported may be linked to orlistat. However, EMA has concluded that the benefit of orlistat continues to outweight its risk.
